Managed Healthcare Executive

Low uptake of shingles vaccine despite strong value proposition for older adults

RZV offers substantial clinical and economic benefits but has low uptake among adults aged 50 and older compared to other vaccines. By 2020, only 10.8% of adults aged 50 and older had completed both ...
Business Wire

AREXVY recommended for adults aged 50-59 at increased risk for severe respiratory syncytial virus (RSV) disease by US Advisory Committee on Immunization Practices

Tony Wood, Chief Scientific Officer, GSK: “We are pleased with ACIP's recommendation to expand the benefits of RSV immunization to more than 13 million adults aged 50-59 who are at increased risk for ...
The American Journal of Managed Care

The Potential Benefits of RSV Vaccine Approval for Adults Aged 50-59

As phase 3 data for the RSV vaccine are leading the FDA to consider expanding the age range to include patients aged 50-59, the panel discusses the potential clinical and economic benefits. What is ...
Monthly Prescribing Reference

ACIP Recommends RSV Vaccine for 50 to 59-Year-Olds at High Risk

The updated recommendation lowers the recommended age for RSV vaccination from 60 to 50 years in adults who are at high risk. The US Centers for Disease Control and Prevention’s (CDC) Advisory ...
Seeking Alpha

ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease

Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74 ACIP recommends adults 50–59 years of age who are at increased risk of severe RSV ...